IMMUNOGENICITY OF RECOMBINANT BCG VACCINES IN RHESUS MONKEYS

重组卡介苗疫苗在恒河猴中的免疫原性

• 批准号: 7562095
• 负责人: NORMAN L LETVIN
• 金额: $ 19.06万
• 依托单位: HARVARD MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-05-01 至 2008-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7562095
• 关键词: Antibody Formation; Attenuated; BCG Vaccine; Calmette-Guerin Bacillus; Cellular Immunity; Computer Retrieval of Information on Scientific Projects Database; Cytotoxic T-Lymphocytes; Engineering; Funding; Grant; HIV vaccine; HIV-1 vaccine; Immunity; Infectious Agent; Institution; Leprosy; Macaca mulatta; Modeling; Mus; Mycobacterium bovis; Recombinants; Research; Research Personnel; Resources; Source; System; Transgenes; Tuberculosis Vaccines; United States National Institutes of Health; Vaccines; Virus; immunogenicity; neutralizing antibody; response; vaccine effectiveness; vector

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. An effective HIV/AIDS vaccine will have to elicit both virus-specific neutralizing antibodies and cytotoxic T lymphocyte (CTL) responses. Marginal immunogenicity and pre-existing anti-vector immunity are likely to limit the effectiveness of the vaccine constructs currently being evaluated. Better vector systems will therefore be needed to induce anti-HIV-1 cellular immunity and prime for neutralizing antibody responses. The attenuated, non-pathogenic Mycobacterium bovis BCG has features that make it attractive as a potential HIV-1 vaccine vector. BCG has been successfully used as a vaccine for tuberculosis (TB) and leprosy, and can be readily engineered to stably express transgenes. Recombinant BCG vaccines (rBCG) have demonstrated immunogenicity and conferred protection against various infectious agents in murine models.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 有效的HIV/AIDS疫苗将不得不引起病毒特异性中和抗体和细胞毒性T淋巴细胞（CTL）反应。边缘免疫原性和预先存在的抗载体免疫可能会限制当前正在评估的疫苗构建体的有效性。因此，将需要更好的载体系统诱导抗HIV-1细胞免疫和中和抗体反应的素质。牛BCG的衰减，非致病性分枝杆菌的特征使其作为潜在的HIV-1疫苗载体具有吸引力。 BCG已成功用作结核病（TB）和麻风病的疫苗，并且可以轻松地设计以稳定地表达转基因。重组BCG疫苗（RBCG）表现出了免疫原性和对鼠模型中各种传染剂的保护。